Neurologic Manifestations of Xeroderma Pigmentosum

Neurologic Manifestations of Xeroderma Pigmentosum

No Results

No Results


Xeroderma pigmentosum (XP) is a group of rare autosomal-recessive inherited disorders characterized by extreme skin sensitivity to ultraviolet (UV) light, abnormal skin pigmentation, and high frequency of skin cancers, especially on sun-exposed skin (see image below). Dermatologic changes are the most conspicuous findings and are mandatory for the diagnosis. [1]

Neurologic involvement is often part of a phenotypic spectrum. Albert Neisser first described neurologic abnormalities associated with xeroderma pigmentosum in 1883. Neurologic involvement in xeroderma pigmentosum was emphasized in 1932 by De Sanctis and Cacchione, who described 3 brothers with xeroderma pigmentosum who had mental retardation, dwarfism, and gonadal hypoplasia. Subsequently, some authors referred to xeroderma pigmentosum associated with CNS abnormalities as De Sanctis-Cacchione syndrome.

In 1987, Kraemer et al reviewed clinical characteristics of 830 patients with xeroderma pigmentosum who were described in 297 articles. These researchers found neurologic abnormalities in 152 (18%) of these patients, a rate similar to those in other reports. Among patients with nervous system involvement, the most common abnormality was mental retardation (80% of subjects with neurologic involvement). Among these patients, the median intelligence quotient (IQ) score was 45, and the range was 15-81. The second most common neurologic abnormality was spasticity or ataxia (30% of subjects with neurologic involvement), followed by microcephaly (24%). [2]

Analysis of 106 patients with xeroderma pigmentosum followed at the National Institutes of Health identified a progressive neurologic degeneration in 25 (24%) patients, and 16 of these patients had complementary group XP-D. [3]

Cleaver’s seminal work in 1968 elucidated the pathophysiology of xeroderma pigmentosum by demonstrating defective DNA repair. Further studies of this defect led to significant progress in the understanding of nucleotide excision repair (NER) mechanisms under normal and pathologic conditions. [4]

UV radiation induces cross-linking (dimerization) between thymine nucleotides. After exposure to UV light, normal cultured cells identify and excise the UV-induced thymine dimers and insert undamaged nucleotides after DNA synthesis and ligation. This repair process, known as unscheduled DNA synthesis, is deficient in xeroderma pigmentosum. Cell complementation analysis of cultured cells from patients with xeroderma pigmentosum demonstrated that xeroderma pigmentosum was genetically heterogeneous for the ability to repair UV-induced thymine dimers.

Fibroblasts from different patients with xeroderma pigmentosum were fused, and DNA repair after UV exposure was assayed. Correction of DNA repair deficiency in the fused cells indicates that each cell line has a unique abnormality of DNA repair. This finding led to identification of 7 specific complementation groups (A through G).

The genes that are responsible for defective NER in each xeroderma pigmentosum complementary group are highly conserved; homologous genes have been discovered in several species ranging from yeast to mammals.

Two overlapping pathways for NER have been proposed: the rapid transcription-coupled repair directed at the transcribed strand and slower global genome repair, which also includes the nontranscribed strand. Most xeroderma pigmentosum complementary groups are defective in both pathways. The complementary group C (XP-C) is a notable exception in which only global genome repair is defective.

The xeroderma pigmentosum variant complementation group (XP-V) has normal unscheduled DNA synthesis after UV exposure. However, the ability to repair DNA is reduced after adding caffeine to cultured cells. This defect is caused by mutations in the (pol)eta polymerase, which initiates translesion synthesis of UV-damaged DNA in an error-free manner.

Xeroderma pigmentosum is a multisystem disorder; sun-exposed skin and eyes (ie, eyelids, conjunctivae) are the most affected tissues. Cutaneous photosensitivity and early development of skin cancer is caused by defective DNA repair. [5]

CNS involvement is due to premature neuronal death.

Necrosis in tissues that are not exposed to UV light suggests that these cells in patients with xeroderma pigmentosum are unable to repair DNA damage from other mutagens (eg, reactive oxygen species, other free radicals). Neurodegeneration probably results from accumulating mutations due to cells’ inability to repair DNA damage. Increased oxidative damage in neurons due to abnormal function of free radical scavengers, such as superoxide dismutase, has been suggested.

The presence of neurologic abnormalities correlates with the degree of NER repair defect; patients with the greatest impairment of DNA repair are more prone to develop neurodegeneration.

Pathologic studies showed diffuse neuronal loss without other histologic hallmarks. Selective degeneration of dopaminergic neurons has been reported in some patients who were affected neurologically. Diffuse axonal loss was seen in the peripheral nerves in patients with clinical evidence of polyneuropathy.

United States

XP-C and XP-D are the most common complementary forms, representing 30% and 20% of all xeroderma pigmentosum cases, respectively. XP-A is rare.


The worldwide frequency of xeroderma pigmentosum is estimated at 1 case in 250,000 population. Frequencies of complementary groups vary significantly in different populations. XP-A accounts for as many as 40% of all cases in Japan. Other complementary groups, with the exception of XP-V (in which all patients have only dermatologic manifestations), are rare. For example, only 3 cases of the XP-B type have been reported.

See the list below:

Skin cancer represents the major morbidity in xeroderma pigmentosum.

The median age of the first cutaneous cancer in xeroderma pigmentosum (most commonly basal cell or squamous cell carcinoma) is 8 years. In striking contrast, the mean age for squamous cell carcinoma in the general population is 58 years.

The incidence of malignant melanoma in patients with xeroderma pigmentosum who are younger than 20 years is 2000-fold higher than in an age-matched US population.

Skin tumors are typically multiple, and patients with as many as 100 tumors have been reported. This may result in disfigurement in severely affected subjects.

Keratitis, together with squamous cell tumors of the conjunctiva and corneoconjunctival junction, is a major source of ophthalmologic morbidity.

Other malignancies also occur at increased frequency in patients with xeroderma pigmentosum. The frequency of inner organ neoplasms, including malignant brain tumors, is estimated to be increased 20-fold compared to subjects without xeroderma pigmentosum.

Mental retardation (or dementia in subjects with adult-onset neurologic deterioration), hearing loss, spasticity, ataxia, and polyneuropathy are the most common morbidity factors in the subset of patients who have with neurologic impairment.

As many as 50% of patients with XP-D manifest neurologic deterioration. Neurologic involvement is rare in patients with XP-C, the most common complementary group in the United States.

Seizures are common and epilepsy may be present in almost 25% of all patients.

Neurologic symptoms are progressive and may result in severe disability.

Many patients become bedridden and incontinent. Some have significant cachexia in the terminal stages despite adequate caloric intake.

Urinary tract infection, sepsis, and aspiration pneumonia are potential complications.

Patients with early onset of neurologic symptoms tend to have more profoundly defective DNA repair, making them more susceptible to skin and inner organ tumors. The median age at death in xeroderma pigmentosum patients with signs of neurodegeneration was 29 years and in patients without any additional neurologic abnormalities was 38 years. [3]

Kraemer et al constructed the Kaplan-Meier survival curve for patients with xeroderma pigmentosum. The following were estimated:

90% probability of surviving to age 13 years

80% probability of surviving to 28 years

70% probability surviving to 40 years

Overall, life expectancy of patients with xeroderma pigmentosum reduced by 30 years

Various comorbid cancers usually cause death.

The most common cause of death in xeroderma pigmentosa patients is skin cancer, at 34%, followed by cancer of internal organs, at 17%.

Progressive neurodegeneration can be a direct cause of death in approximately one third of patients.

All ethnic groups are affected similarly.

Both sexes are affected equally.

See the list below:

Only 5% of patients manifest the first symptoms after age 14 years.

The median age of symptom onset is approximately 2 years.

Lehmann AR, McGibbon D, Stefanini M. Xeroderma pigmentosum. Orphanet J Rare Dis. 2011 Nov 1. 6:70. [Medline]. [Full Text].

Kraemer KH, Lee MM, Scotto J. Xeroderma pigmentosum. Cutaneous, ocular, and neurologic abnormalities in 830 published cases. Arch Dermatol. 1987 Feb. 123(2):241-50. [Medline].

Bradford PT, Goldstein AM, Tamura D, Khan SG, Ueda T, Boyle J, et al. Cancer and neurologic degeneration in xeroderma pigmentosum: long term follow-up characterises the role of DNA repair. J Med Genet. 2011 Mar. 48(3):168-76. [Medline]. [Full Text].

Feltes BC, Bonatto D. Overview of xeroderma pigmentosum proteins architecture, mutations and post-translational modifications. Mutat Res Rev Mutat Res. 2015 Jan-Mar. 763:306-320. [Medline].

Tamura D, DiGiovanna JJ, Khan SG, Kraemer KH. Living with xeroderma pigmentosum: comprehensive photoprotection for highly photosensitive patients. Photodermatol Photoimmunol Photomed. 2014 Apr-Jun. 30(2-3):146-52. [Medline].

Mimaki T, Itoh N, Abe J, et al. Neurological manifestations in xeroderma pigmentosum. Ann Neurol. 1986 Jul. 20(1):70-5. [Medline].

Anttinen A, Koulu L, Nikoskelainen E, Portin R, Kurki T, Erkinjuntti M, et al. Neurological symptoms and natural course of xeroderma pigmentosum. Brain. 2008 Aug. 131:1979-89. [Medline].

Fekete R. Xeroderma pigmentosum/de sanctis-cacchione syndrome: unusual cause of ataxia. Case Rep Neurol. 2014 Jan. 6(1):83-7. [Medline]. [Full Text].

Jaspers NG, Raams A, Silengo MC, Wijgers N, Niedernhofer LJ, Robinson AR, et al. First reported patient with human ERCC1 deficiency has cerebro-oculo-facio-skeletal syndrome with a mild defect in nucleotide excision repair and severe developmental failure. Am J Hum Genet. 2007 Mar. 80(3):457-66. [Medline].

Larson DM, Cunningham BB. Photodynamic Therapy in a Teenage Girl with Xeroderma Pigmentosum Type C. Pediatr Dermatol. 2012 Jan 26. [Medline].

Cleaver JE. Defective repair replication of DNA in xeroderma pigmentosum. Nature. 1968 May 18. 218(5142):652-6. [Medline].

De Sanctinis C, Cacchione A. L’idiozia xerodermica. Riv Sepr Freniatr. 1932. 56:269-292.

Hakamada S, Watanabe K, Sobue G, et al. Xeroderma pigmentosum: neurological, neurophysiological and morphological studies. Eur Neurol. 1982. 21(2):69-76. [Medline].

Hayashi M, Araki S, Kohyama J, et al. Oxidative nucleotide damage and superoxide dismutase expression in the brains of xeroderma pigmentosum group A and Cockayne syndrome. Brain Dev. 2005 Jan. 27(1):34-8. [Medline].

Johnson RT, Squires S. The XPD complementation group. Insights into xeroderma pigmentosum, Cockayne’s syndrome and trichothiodystrophy. Mutat Res. 1992 Mar. 273(2):97-118. [Medline].

Kohyama J, Furushima W, Sugawara Y, et al. Convulsive episodes in patients with group A xeroderma pigmentosum. Acta Neurol Scand. 2005 Oct. 112(4):265-9. [Medline].

Lehmann AR. DNA repair-deficient diseases, xeroderma pigmentosum, Cockayne syndrome and trichothiodystrophy. Biochimie. 2003 Nov. 85(11):1101-11. [Medline].

Mimaki T, Tagawa T, Tanaka J, et al. EEG and CT abnormalities in xeroderma pigmentosum. Acta Neurol Scand. 1989 Aug. 80(2):136-41. [Medline].

Moriwaki S, Nishigori C, Imamura S, et al. A case of xeroderma pigmentosum complementation group F with neurological abnormalities. Br J Dermatol. 1993 Jan. 128(1):91-4. [Medline].

Nance MA, Berry SA. Cockayne syndrome: review of 140 cases. Am J Med Genet. 1992 Jan 1. 42(1):68-84. [Medline].

Rapin I, Weidenheim K, Lindenbaum Y, et al. Cockayne syndrome in adults: review with clinical and pathologic study of a new case. J Child Neurol. 2006 Nov. 21(11):991-1006. [Medline].

Robbins JH, Brumback RA, Mendiones M, et al. Neurological disease in xeroderma pigmentosum. Documentation of a late onset type of the juvenile onset form. Brain. 1991 Jun. 114 ( Pt 3):1335-61. [Medline].

Robbins JH, Brumback RA, Moshell AN. Clinically asymptomatic xeroderma pigmentosum neurological disease in an adult: evidence for a neurodegeneration in later life caused by defective DNA repair. Eur Neurol. 1993. 33(3):188-90. [Medline].

Robbins JH, Kraemer KH, Lutzner MA, et al. Xeroderma pigmentosum. An inherited diseases with sun sensitivity, multiple cutaneous neoplasms, and abnormal DNA repair. Ann Intern Med. 1974 Feb. 80(2):221-48. [Medline].

Roytta M, Anttinen A. Xeroderma pigmentosum with neurological abnormalities. A clinical and neuropathological study. Acta Neurol Scand. 1986 Feb. 73(2):191-9. [Medline].

Weeda G, Ma LB, van Ham RC, et al. Structure and expression of the human XPBC/ERCC-3 gene involved in DNA repair disorders xeroderma pigmentosum and Cockayne’s syndrome. Nucleic Acids Res. 1991 Nov 25. 19(22):6301-8. [Medline].

Weeda G, van Ham RC, Vermeulen W, et al. A presumed DNA helicase encoded by ERCC-3 is involved in the human repair disorders xeroderma pigmentosum and Cockayne’s syndrome. Cell. 1990 Aug 24. 62(4):777-91. [Medline].

Peter Hedera, MD, PhD Associate Professor, Department of Neurology, Vanderbilt University School of Medicine

Peter Hedera, MD, PhD is a member of the following medical societies: American Academy of Neurology, American College of Medical Genetics and Genomics, American Neurological Association

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Kenneth J Mack, MD, PhD Senior Associate Consultant, Department of Child and Adolescent Neurology, Mayo Clinic

Kenneth J Mack, MD, PhD is a member of the following medical societies: American Academy of Neurology, Child Neurology Society, Phi Beta Kappa, Society for Neuroscience

Disclosure: Nothing to disclose.

Amy Kao, MD Attending Neurologist, Children’s National Medical Center

Amy Kao, MD is a member of the following medical societies: American Academy of Neurology, American Epilepsy Society, Child Neurology Society

Disclosure: Have stock (managed by a financial services company) in healthcare companies including AbbVie, Allergan, Celgene, Cellectar Biosciences, Danaher Corp, Mckesson.

Robert Stanley Rust, Jr, MD, MA Thomas E Worrell Jr Professor of Epileptology and Neurology, Co-Director of FE Dreifuss Child Neurology and Epilepsy Clinics, Director, Child Neurology, University of Virginia School of Medicine; Chair-Elect, Child Neurology Section, American Academy of Neurology

Robert Stanley Rust, Jr, MD, MA is a member of the following medical societies: Child Neurology Society, Society for Pediatric Research, American Headache Society, International Child Neurology Association, American Academy of Neurology, American Epilepsy Society, American Neurological Association

Disclosure: Nothing to disclose.

Neurologic Manifestations of Xeroderma Pigmentosum

Research & References of Neurologic Manifestations of Xeroderma Pigmentosum|A&C Accounting And Tax Services